Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents.
BMC Cardiovasc Disord
; 22(1): 60, 2022 02 17.
Article
em En
| MEDLINE
| ID: mdl-35172738
ABSTRACT
BACKGROUND:
Coronary artery aneurysms after drug eluting stents are rare. We present a case series of type II coronary aneurysms after implantation of Everolimus eluting stents including patients developing giant aneurysms with a toxic course. CASE PRESENTATION Over a span of 3.5 years at our center 2572 patients were implanted Everolimus eluting stents out of which 4 patients developed coronary type II aneurysms an incidence of 0.00156 whereas 5838 patients were implanted Sirolimus eluting 2nd generation stents out of which 2 patients developed similar aneurysms with an incidence of 0.00034. The slight increase in incidence in Everolimus stents does not reach statistical significance (p = 0.054) and is limited by single centre non randomized study. We also propose a hypothesis that the slight increase in the incidence maybe due to allergy to Methacrylate present in Everolimus eluting Xience stent's primer which is absent in other Sirolimus eluting stents used at our center but that needs to be further investigated. We also found some patients who developed giant aneurysms including Left main aneurysms. In our series operative repair of these patients had better outcomes than covered stent deployment but larger trials maybe needed to confirm the same.CONCLUSIONS:
Coronary artery aneurysms after stent implantation are rare but occasionally giant aneurysms are formed with a toxic course. The incidence and morphology of aneurysms after Everolimus and Sirolimus eluting stent deployment do not differ much.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Aneurisma Coronário
/
Doença da Artéria Coronariana
/
Fármacos Cardiovasculares
/
Sirolimo
/
Stents Farmacológicos
/
Intervenção Coronária Percutânea
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article